Lipocine reports upbeat study results

Lipocine Inc. (Nasdaq: LPCN) reported positive results from a Phase 3 clinical study of its testosterone replacement LPCN 1021 sending the stock price soaring $2.33 to $7.55.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.